Morgan Stanley Health Sciences I
522 Fifth Avenue Jersey City NJ 07311
Map
Phone: 800-869-6397
| Category: | Specialty-Health | | Fund Family: | Morgan Stanley | | Net Assets: | 470.00K | | Year-to-Date Return: | -0.19% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 28-Jul-97 |
|
Michael Nolan
Lead Manager since
30-Jun-08 | | | Nolan has been associated with the Investment Adviser in an investment management capacity since November 2005. Prior to November 2005, he was responsible for Morgan Stanley & Companys collateralized debt obligation business in Europe. |
| Min Initial Investment: | $5,000,000 | | Min Initial Investment, IRA: | $0 | | Min Initial Investment, AIP: | $0 | | Min Subsequent Investment: | $0 | | Min Subsequent Investment, IRA: | $0 | | Min Subsequent Investment, AIP: | $0 |
|
| |
| The investment seeks capital appreciation. The fund normally invests at least 80% of assets in common stocks (including depositary receipts) of health science companies throughout the world. It may invest the remaining 20% of assets in the common stock of non-health science companies, preferred stock and investment-grade fixed-income securities. The fund may invest up to 25% of assets in emerging-market securities. It also may invest a portion of assets in convertible securities and futures and may utilize forward foreign currency exchange contracts. |
| Last Dividend
| N/A | | Last Cap Gain
(14-Dec-07):
| 3.73 | | Annual Holdings Turnover
| 62.00% | | Average for Category:
| 101.53% |
|
| Expense | HCRDX | Category
Avg | | Total Expense Ratio: | 1.29%
| 1.67% | | Max 12b1 Fee: | 0.00%
| N/A | | Max Front End Sales Load: | 0.00%
| 5.30% | | Max Deferred Sales Load: | 0.00%
| 2.94% | | 3 Yr Expense Projection*: |
$409 | $721 | | 5 Yr Expense Projection*: |
$708 | $1,073 | | 10 Yr Expense Projection*: |
$1,556 | $2,092 |
|
|
1.12% Nasdaq 
0.14 (0.89%) 
Profile
